Not logged inTyrosine kinase inhibitor, masitinib, limits neuronal damage, as measured by serum neurofilament light chain concentration in a model of neuroimmune-driven neurodegenerative disease
Hermine, Olivier; Gros, Laurent; Tran, Truong-An; Loussaief, Lamya; Flosseau, Kathleen; Moussy, Alain; Mansfield, Colin D.; Vermersch, Patrick .png)
Share.png)
SaveMasitinib for mild-to-moderate Alzheimer's disease: results from a randomized, placebo-controlled, phase 3, clinical trial (vol 15, 39, 2023)Dubois, Bruno; Lopez-Arrieta, Jesus; Lipschitz, Stanley; Doskas, Triantafyllos; Spiru, Luiza; Moroz, Svitlana; Venger, Olena; Vermersch, Patrick; Moussy, Alain D.; Mansfield, Colin; Hermine, Olivier; Tsolaki, Magda Share Save Masitinib for mild-to-moderate Alzheimer's disease: results from a randomized, placebo-controlled, phase 3, clinical trialDubois, Bruno; Lopez-Arrieta, Jesus; Lipschitz, Stanley; Triantafyllos, Doskas; Spiru, Luiza; Moroz, Svitlana; Venger, Olena; Vermersch, Patrick; Moussy, Alain; Mansfield, Colin D. D.; Hermine, Olivier; Tsolaki, Magda Share Save Efficacy and Safety of Masitinib in Corticosteroid-Dependent Severe Asthma: A Randomized Placebo-Controlled TrialDavidescu, Lavinia; Ursol, Grigoriy; Korzh, Oleksii; Deshmukh, Vikranth; Kuryk, Lesia; Nortje, Monja-Marie; Godlevska, Olga; Devouassoux, Gilles; Khodosh, Eduard; Israel, Elliot; Moussy, Alain; Mansfield, Colin; Hermine, Olivier; Chanez, Pascal Share Save Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis A Randomized, Phase 3, Clinical TrialVermersch, Patrick; Brieva-Ruiz, Luis; Fox, Robert J.; Paul, Friedemann; Ramio-Torrenta, Lluis; Schwab, Matthias; Moussy, Alain; Mansfield, Colin; Hermine, Olivier; Maciejowski, Maciej Share Save Late Breaking Abstract - Masitinib in severe asthma: Results from a randomized, phase 3 trialDavidescu, Lavinia; Chanez, Pascal; Ursol, Grigoriy; Korzh, Oleksii; Deshmukh, Vikranth; Kuryk, Lesia; Monja-Marie, Nortje; Godlevska, Olga; Devouassoux, Gilles; Khodosh, Eduard; Israel, Elliot; Mansfield, Colin; Hermine, Olivier Share Save Dual protein kinase and nucleoside kinase modulators for rationally designed polypharmacologyHammam, Kahina; Saez-Ayala, Magali; Rebuffet, Etienne; Gros, Laurent; Lopez, Sophie; Hajem, Berengere; Humbert, Martine; Baudelet, Emilie; Audebert, Stephane; Betzi, Stephane; Lugari, Adrien; Combes, Sebastien; Letard, Sebastien; Casteran, Nathalie; Mansfield, Colin; Moussy, Alain; De Sepulveda, Paulo; Morelli, Xavier; Dubreuil, Patrice Share Save Share Save Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 studyLortholary, Olivier; Chandesris, Marie Olivia; Livideanu, Cristina Bulai; Paul, Carle; Guillet, Gerard; Jassem, Ewa; Niedoszytko, Marek; Barete, Stephane; Verstovsek, Srdan; Grattan, Clive; Damaj, Gandhi; Canioni, Danielle; Fraitag, Sylvie; Lhermitte, Ludovic; Georgin-Lavialle, Sophie; Frenzel, Laurent; Afrin, Lawrence B.; Hanssens, Katia; Agopian, Julie; Gaillard, Raphael; Kinet, Jean-Pierre; Auclair, Christian; Mansfield, Colin; Moussy, Alain; Dubreuil, Patrice; Hermine, Olivier Share Save Masitinib plus FOLFIRI for second-line treatment of metastatic colorectal cancer: 2-year follow-up of phase 2, open label trialTaieb, J.; Borg, C.; Lecomte, T.; Lepere, C.; Chatellier, T.; Smith, D.; Dubreuil, P.; Mansfield, C.; Moussy, A.; Hermine, O. Share Save Share Save Phase 1b/2 study results for masitinib plus irinotecan in second-line treatment of esophagogastric adenocarcinomaZaanan, A.; Bennouna, J.; Hiret, S.; Douillard, J. Y.; Bouche, O.; Tougeron, D.; Lecomte, T.; Ezenfis, J.; Lepere, C.; Mansfield, C.; Moussy, A.; Dubreuil, P.; Hermine, O.; Taieb, J. Share Save A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancerDeplanque, G.; Demarchi, M.; Hebbar, M.; Flynn, P.; Melichar, B.; Atkins, J.; Nowara, E.; Moye, L.; Piquemal, D.; Ritter, D.; Dubreuil, P.; Mansfield, C. D.; Acin, Y.; Moussy, A.; Hermine, O.; Hammel, P. Share Save Share Save Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: A randomized controlled open-label trialAdenis, A.; Blay, J. -Y.; Bui-Nguyen, B.; Bouche, O.; Bertucci, F.; Isambert, N.; Bompas, E.; Chaigneau, L.; Domont, J.; Ray-Coquard, I.; Blesius, A.; Van Tine, B. A.; Bulusu, V. R.; Dubreuil, P.; Mansfield, C. D.; Acin, Y.; Moussy, A.; Hermine, O.; Le Cesne, A. Share Save Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: A phase 2a studyPaul, Carle; Sans, Beatrix; Suarez, Felipe; Casassus, Philippe; Barete, Stephane; Lanternier, Fanny; Grandpeix-Guyodo, Catherine; Dubreuil, Patrice; Palmerini, Fabienne; Mansfield, Colin D.; Gineste, Paul; Moussy, Alain; Hermine, Olivier; Lortholary, Olivier Share Save Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancersSoria, J. C.; Massard, C.; Magne, N.; Bader, Th.; Mansfield, C. D.; Blay, J. Y.; Bui, B. N.; Moussy, A.; Hermine, O.; Armand, J. P. Share Save Share Save Share Save Share Save 
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
